Dr. Adam Sewell, MD breaks down inflammaging — the persistent, low-grade inflammation that accelerates degeneration across the body's systems — and what actually moves the needle on it.
Listen →Andrew Huberman talks with mitochondria researcher Dr. Jared Rutter (University of Utah, HHMI) about how mitochondria generate cellular energy, regulate cell growth and division, and link to aging and cancer. The conversation frames metabolism as an emergent property of trillions of individual mitochondria-containing cells.
Listen →A new nanobody-based delivery system precisely targets healthy donor mitochondria to damaged neurons, cardiac cells, and other specific cell types — rescuing degenerating neurons in both a human optic-nerve-atrophy cell model and mice. Still preclinical, but a concrete step toward treating primary mitochondrial diseases like TK2 deficiency.
Read source →Dr. Martin Picard (Columbia) explains how mitochondria translate behavior, psychology, and mindset into cellular energy production, and how exercise, nutrition, sleep, and stress reduction measurably affect mitochondrial function and aging markers.
Listen →Dr. Martin Picard (Columbia) explains how mitochondria translate behavior, psychology, and mindset into cellular energy production, and how exercise, nutrition, sleep, and stress reduction measurably affect mitochondrial function and aging markers.
Listen →Three geroscientists (rheumatology, neurology, and critical care) map how chronic low-grade inflammation shows up across specialties — from rheumatologic disease to traumatic brain injury — and where the gap is between wellness-marketing claims and actual evidence on inflammaging tests and treatments.
Listen →In a placebo-controlled RCT of 50 healthy middle-aged adults, 1,000 mg/day of urolithin A for 4 weeks expanded naive, less-exhausted CD8+ T cells and measurably increased mitochondrial biogenesis within those immune cells — a rare case of a supplement showing a measurable immune-aging effect this quickly. Conducted with the Buck Institute for Research on Aging.
Read source →Eric Verdin, CEO of the Buck Institute for Research on Aging, on how immune aging — thymic shrinkage, narrowing T-cell diversity, weaker vaccine response — acts as a rate-limiting step in aging, and how chronic inflammation is both a consequence and an accelerant of it. Also covers NAD decline and CD38, the real limits of NMN/NR/IV NAD, rapamycin, and what aging clocks can and can't tell you.
Listen →The inflammaging signature derived from an Italian cohort (InCHIANTI) replicated in another industrialized population (Singapore), but largely vanished in two non-industrialized groups — the Tsimane of the Bolivian Amazon and the Orang Asli of Peninsular Malaysia. In those groups inflammation tracked infection burden rather than age, and showed little association with age-related disease. Suggests inflammaging may be substantially a byproduct of industrialized environments rather than a fixed feature of human aging.
Read source →Ralph DeFronzo, M.D. walks through the pathophysiology of insulin resistance across muscle, liver, and fat, and how it's measured, prevented, diagnosed, and treated.
Listen →Ralph DeFronzo, M.D. — the researcher who helped bring metformin to the US and developed SGLT2 inhibitors — walks through the pathophysiology of insulin resistance across muscle, liver, and fat, and how it's measured, prevented, diagnosed, and treated.
Listen →Huberman and Attia dig into the NAD+ pathway, comparing NAD, NMN, and NR supplementation, routes of administration, and what the clinical literature actually supports for longevity.
Listen →López-Otín, Blasco, Partridge, Serrano & Kroemer expand the hallmarks of aging from 9 to 12, including mitochondrial dysfunction — and map how each hallmark reinforces the others.
Read source →A 4-month, placebo-controlled RCT (NCT03464500) found ~12% gains in muscle strength and improved mitochondrial biomarkers (lower plasma acylcarnitines and CRP) from the mitophagy-activating postbiotic Urolithin A.
Read source →This PRISMA systematic review pooled 113 studies (33 human, 80 rodent) on NAD+-boosting compounds like NR and NMN. It found rodent studies often showed metabolic and mitochondrial benefits, but in humans, oral NR/NMN reliably raised NAD+-related biomarkers while effects on real functional and health outcomes were mixed or null, and no outcomes trials existed yet for IV/wellness-clinic NAD+ infusions.
Read source →A 2026 Nature Metabolism review of how mitophagy, biogenesis, and mitochondrial network dynamics change with age, and what that means for healthspan interventions targeting mitochondrial quality rather than just quantity.
Read source →Attia and Huberman work through the research on metformin as a longevity drug. Along the way Attia explains how insulin resistance develops — starting in muscle — and its role in type 2 diabetes. A useful look at how to read the evidence behind a much-hyped intervention.
Listen →The design paper for a randomized, double-blind, placebo-controlled trial testing whether clazakizumab, an antibody that blocks interleukin-6, can improve or slow decline in physical, cognitive and vascular function in adults aged 70 and over with low-to-moderate physical function. It is a direct test of the geroscience idea that targeting inflammation itself can extend healthspan. No results yet — this paper describes the rationale and protocol.
Read source →Maps how age-associated chronic inflammation interacts with the other eleven hallmarks of aging, arguing the crosstalk forms a self-reinforcing cycle that accelerates cellular decline. A good orientation piece for why inflammation sits near the centre of the aging network rather than off to one side.
Read source →